Fact Sheet

Gene Therapies Could Reduce Beta Thalassemia Costs by 41%

Gene therapies could reduce Beta Thalassemia costs by 41% per patient over five years, resulting in $325,000 in total potential savings. Gene therapies meet a previous unmet need, empowering patients to lead healthier lives with renewed independence, improved quality of life and avoiding burdensome transfusions and associated side effects.